GeneDx Holdings Corp.
$ 66.86
9.64%
14 Apr - close price
- Market Cap 1,958,245,000 USD
- Current Price $ 66.86
- High / Low $ 67.14 / 61.60
- Stock P/E N/A
- Book Value 10.54
- EPS -0.73
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.08 %
- 52 Week High 170.87
- 52 Week Low 55.17
About
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Analyst Target Price
$148.89
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-10-28 | 2025-07-28 | 2025-04-28 | 2025-02-18 | 2024-10-29 | 2024-07-30 | 2024-04-29 | 2024-02-20 | 2023-10-30 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.14 | 0.49 | 0.5 | 0.2732 | 0.6353 | 0.04 | -0.1 | -0.33 | -0.69 | -0.82 | -1.64 | -2.44 |
| Estimated EPS | 0.0886 | 0.41 | 0.118 | -0.67 | 0.1033 | -0.21 | -0.3 | -0.67 | -0.75 | -1.31 | -1.31 | -2.14 |
| Surprise | 0.0514 | 0.08 | 0.382 | 0.9432 | 0.532 | 0.25 | 0.2 | 0.34 | 0.06 | 0.49 | -0.33 | -0.3 |
| Surprise Percentage | 58.0135% | 19.5122% | 323.7288% | 140.7761% | 515.0048% | 119.0476% | 66.6667% | 50.7463% | 8% | 37.4046% | -25.1908% | -14.0187% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WGS
2026-04-06 08:39:39
GeneDx Holdings (WGS) is experiencing weakening sentiment due to institutional outflows and bearish technical signals, despite a core investment narrative around genomics adoption and AI capabilities. While a new $100 million loan from Blackstone provides liquidity, it also increases leverage, making the company more sensitive to slowdowns. Analysts show a wide range of future projections for the company, highlighting diverse investor perspectives on its potential.
2026-03-31 09:39:38
This page provides access to GeneDx Holdings SEC filings (WGSWW), including 10-K, 10-Q, 8-K, and insider trading forms. Each filing includes AI-powered summaries to help investors understand key points regarding warrant terms, governance changes, and compensation policies. The platform ensures real-time updates from the SEC’s EDGAR system, making it a comprehensive resource for regulatory disclosures and corporate events.
2026-03-31 05:10:42
GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units (RSUs) and subsequently sold 46,933 shares to cover tax withholding obligations. These "sell to cover" transactions were non-discretionary and executed at weighted average prices between $60.93 and $65.61 per share. After these transactions, the CEO beneficially owns 91,514 shares of Class A common stock, along with additional RSUs and stock options.
2026-03-31 05:10:42
GeneDx Holdings Corp.'s CFO, Kevin Feeley, exercised 16,250 restricted stock units (RSUs) and subsequently sold 8,818 Class A Common Stock shares. These sales, conducted at weighted average prices between $60s and $65s per share, were explicitly for covering tax withholding obligations associated with the RSU vesting, categorized as a "sell to cover" transaction rather than a discretionary trade. Following these transactions, Feeley beneficially owns 34,580 Class A Common Stock shares, with additional contingent rights to 93,173 RSU shares and options for 25,906 shares.
2026-03-30 22:10:42
GeneDx Holdings CFO Kevin Feeley sold 7,718 shares of Class A Common Stock for approximately $557,051 on March 26, 2026, though he also acquired 16,250 shares through restricted stock unit exercises at $0. This comes as the stock has fallen 17% in the past week, yet analysts maintain Buy ratings with high price targets due to strong Q4 revenue and positive growth outlook, despite new competition.
2026-03-26 16:40:46
GeneDx Holdings is gaining positive analyst attention after data presented at the ACMG Annual Meeting showed its genomic tests can reduce healthcare costs and resource use, particularly appealing to payers. While this strengthens the company's case for reimbursement expansion, investors need to be aware of potential risks related to shifts in reimbursement policies or pricing pressures that could impact future value capture despite a recent $100 million term loan from Blackstone. The company projects significant revenue and earnings growth by 2028, leading to a substantial upside in its fair value estimates.
